Natasha Arulappan
Johannesburg, GT, South Africa
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Final 192-Week Efficacy and Safety Results of the ADVANCE Trial, Comparing 3 First-line Antiretroviral Regimens.
Journal: Open forum infectious diseases
Published: August 21, 2023
Differential Responsiveness of the Platelet Biomarkers, Systemic CD40 Ligand, CD62P, and Platelet-Derived Growth Factor-BB, to Virally-Suppressive Antiretroviral Therapy.
Journal: Frontiers in immunology
Published: August 12, 2020
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
Journal: The lancet. HIV
Published: June 05, 2020
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.
Journal: The New England journal of medicine
Published: July 25, 2019
Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Low-Dose Stavudine Over 96 Weeks: A Multicountry Randomized, Noninferiority Trial.
Journal: Journal of acquired immune deficiency syndromes (1999)
Published: January 15, 2019
CD4 cell count variability with repeat testing in South Africa: Should reporting include both absolute counts and ranges of plausible values?
Journal: International journal of STD & AIDS
Published: May 12, 2018
Is laboratory screening prior to antiretroviral treatment useful in Johannesburg, South Africa? Baseline findings of a clinical trial.
Journal: BMC public health
Published: August 24, 2017
Showing 1-8 of 8
Last Updated: 09/26/2026